Melinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug Design
21. April 2017 09:56 ET
|
Melinta Therapeutics
New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that...
Melinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient Types
21. April 2017 09:37 ET
|
Melinta Therapeutics
New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that the...